<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20241207011457&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20241207011457&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 07 Dec 2024 06:14:58 +0000</lastbuilddate>
<pubDate>Fri, 06 Dec 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Diagnostic and Prognostic Performance of High-Sensitivity Cardiac Troponin T vs I</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39641739/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26:S0735-1097(24)10029-0. doi: 10.1016/j.jacc.2024.10.076. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39641739/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39641739</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.076>10.1016/j.jacc.2024.10.076</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39641739</guid>
<pubDate>Fri, 06 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Luca Koechlin</dc:creator>
<dc:creator>Jasper Boeddinghaus</dc:creator>
<dc:creator>Dimitrios Doudesis</dc:creator>
<dc:creator>Pedro Lopez-Ayala</dc:creator>
<dc:creator>Tobias Zimmermann</dc:creator>
<dc:creator>Klara Rumora</dc:creator>
<dc:creator>Jeanne du Fay de Lavallaz</dc:creator>
<dc:creator>Ziwen Li</dc:creator>
<dc:creator>Kuan Ken Lee</dc:creator>
<dc:creator>Andrew R Chapman</dc:creator>
<dc:creator>Karin Wildi</dc:creator>
<dc:creator>Danielle M Gualandro</dc:creator>
<dc:creator>Muntadher Al Karam</dc:creator>
<dc:creator>Maria Rubini Giménez</dc:creator>
<dc:creator>Gabrielle Huré</dc:creator>
<dc:creator>Òscar Miró</dc:creator>
<dc:creator>Zoe Klein</dc:creator>
<dc:creator>Paolo Bima</dc:creator>
<dc:creator>Desiree Wussler</dc:creator>
<dc:creator>Michael Christ</dc:creator>
<dc:creator>Ivo Strebel</dc:creator>
<dc:creator>F Javier Martin-Sanchez</dc:creator>
<dc:creator>Damian Kawecki</dc:creator>
<dc:creator>Dagmar I Keller</dc:creator>
<dc:creator>Oliver Reuthebuch</dc:creator>
<dc:creator>Katharina Rentsch</dc:creator>
<dc:creator>Anna Marsano</dc:creator>
<dc:creator>Andreas Buser</dc:creator>
<dc:creator>Thomas Nestelberger</dc:creator>
<dc:creator>Christian Puelacher</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:creator>Nicholas L Mills</dc:creator>
<dc:creator>Christian Mueller</dc:creator>
<dc:creator>APACE, BASEL VIII, BASEL IX and High-STEACS Investigators</dc:creator>
<dc:date>2024-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Diagnostic and Prognostic Performance of High-Sensitivity Cardiac Troponin T vs I</dc:title>
<dc:identifier>pmid:39641739</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.076</dc:identifier>
</item>
<item>
<title>The Coming AI Revolution in Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39641738/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 23:S0735-1097(24)10286-0. doi: 10.1016/j.jacc.2024.10.093. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39641738/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39641738</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.093>10.1016/j.jacc.2024.10.093</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39641738</guid>
<pubDate>Fri, 06 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Sneha S Jain</dc:creator>
<dc:creator>Ashish Sarraju</dc:creator>
<dc:creator>Nigam H Shah</dc:creator>
<dc:creator>Kevin A Schulman</dc:creator>
<dc:creator>Euan A Ashley</dc:creator>
<dc:creator>Robert A Harrington</dc:creator>
<dc:creator>Kenneth W Mahaffey</dc:creator>
<dc:date>2024-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Coming AI Revolution in Clinical Trials</dc:title>
<dc:identifier>pmid:39641738</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.093</dc:identifier>
</item>
<item>
<title>Digital Health Technologies for Cardiometabolic Disease and Diabetes: A Perspective From the U.S. Food and Drug Administration</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39641737/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 19:S0735-1097(24)10028-9. doi: 10.1016/j.jacc.2024.10.075. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39641737/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39641737</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.075>10.1016/j.jacc.2024.10.075</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39641737</guid>
<pubDate>Fri, 06 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Haider J Warraich</dc:creator>
<dc:creator>Bray Patrick-Lake</dc:creator>
<dc:creator>Anindita Saha</dc:creator>
<dc:creator>Leeda Rashid</dc:creator>
<dc:creator>Vinay Pai</dc:creator>
<dc:creator>Ali Abbasi</dc:creator>
<dc:creator>Matthew C Diamond</dc:creator>
<dc:creator>Troy Tazbaz</dc:creator>
<dc:creator>Robert M Califf</dc:creator>
<dc:date>2024-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Digital Health Technologies for Cardiometabolic Disease and Diabetes: A Perspective From the U.S. Food and Drug Administration</dc:title>
<dc:identifier>pmid:39641737</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.075</dc:identifier>
</item>
<item>
<title>The Patient Behind the Doctor</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39641736/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 23:S0735-1097(24)09963-7. doi: 10.1016/j.jacc.2024.10.073. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39641736/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39641736</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.073>10.1016/j.jacc.2024.10.073</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39641736</guid>
<pubDate>Fri, 06 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Denisa Metani</dc:creator>
<dc:date>2024-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Patient Behind the Doctor</dc:title>
<dc:identifier>pmid:39641736</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.073</dc:identifier>
</item>
<item>
<title>The Importance of Growing the Next Generation of Global Cardiovascular Leaders</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39641735/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 27:S0735-1097(24)10425-1. doi: 10.1016/j.jacc.2024.11.010. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39641735/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39641735</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.010>10.1016/j.jacc.2024.11.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39641735</guid>
<pubDate>Fri, 06 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Cathleen Biga</dc:creator>
<dc:creator>Wael Al Mahmeed</dc:creator>
<dc:creator>Assembly of International Governors Steering Committee</dc:creator>
<dc:date>2024-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Importance of Growing the Next Generation of Global Cardiovascular Leaders</dc:title>
<dc:identifier>pmid:39641735</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.010</dc:identifier>
</item>
<item>
<title>In the Wake of OCEANIC-AF, Is Equipoise Regarding Factor XI Inhibition Still Afloat?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39641734/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26:S0735-1097(24)10317-8. doi: 10.1016/j.jacc.2024.10.105. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39641734/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39641734</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.105>10.1016/j.jacc.2024.10.105</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39641734</guid>
<pubDate>Fri, 06 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>C Michael Gibson</dc:creator>
<dc:date>2024-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>In the Wake of OCEANIC-AF, Is Equipoise Regarding Factor XI Inhibition Still Afloat?</dc:title>
<dc:identifier>pmid:39641734</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.105</dc:identifier>
</item>
<item>
<title>Dynamic Trends and Practice Patterns in Femoropopliteal Revascularization From 2016 Through 2023</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39641733/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26:S0735-1097(24)10314-2. doi: 10.1016/j.jacc.2024.10.102. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39641733/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39641733</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.102>10.1016/j.jacc.2024.10.102</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39641733</guid>
<pubDate>Fri, 06 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Joseph M Kim</dc:creator>
<dc:creator>Siling Li</dc:creator>
<dc:creator>Yang Song</dc:creator>
<dc:creator>Robert W Yeh</dc:creator>
<dc:creator>Eric A Secemsky</dc:creator>
<dc:date>2024-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Dynamic Trends and Practice Patterns in Femoropopliteal Revascularization From 2016 Through 2023</dc:title>
<dc:identifier>pmid:39641733</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.102</dc:identifier>
</item>
<item>
<title>Aortic Valve Replacement vs Clinical Surveillance in Asymptomatic Severe Aortic Stenosis: A Systematic Review and Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39641732/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this meta-analysis of 4 RCTs, early AVR was associated with a significant reduction in unplanned cardiovascular or HF hospitalization and stroke and no differences in all-cause and cardiovascular mortality compared with CS.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 18:S0735-1097(24)10419-6. doi: 10.1016/j.jacc.2024.11.006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Current guidelines recommend a strategy of clinical surveillance (CS) for patients with asymptomatic severe aortic stenosis (AS) and a normal left ventricular ejection fraction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to conduct a study-level meta-analysis of randomized controlled trials (RCTs) evaluating the effect of early aortic valve replacement (AVR) compared with CS in patients with asymptomatic severe AS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Studies were quantitatively assessed in a meta-analysis using random-effects modeling. Prespecified outcomes included all-cause and cardiovascular mortality, unplanned cardiovascular or heart failure (HF) hospitalization, and stroke. The meta-analysis is registered at the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY202490002).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Four RCTs were identified, including a total of 1,427 patients (719 in the early AVR group and 708 in the CS group). At an average follow-up time of 4.1 years, early AVR was associated with a significant reduction in unplanned cardiovascular or HF hospitalization (pooled rate 14.6% vs 31.9%; HR: 0.40; 95% CI: 0.30-0.53; I<sup>2</sup> = 4%; P &lt; 0.01) and stroke (pooled rate 4.5% vs 7.2%; HR: 0.62; 95% CI: 0.40-0.97; I<sup>2</sup> = 0%; P = 0.03). No differences in all-cause mortality (pooled rate 9.7% vs 13.7%; HR: 0.68; 95% CI: 0.40-1.17; I<sup>2</sup> = 61%; P = 0.17) and cardiovascular mortality (pooled rate 5.1% vs 8.3%; HR: 0.67; 95% CI: 0.35-1.29; I<sup>2</sup> = 50%; P = 0.23) were observed with early AVR compared with CS, although there was a high degree of heterogeneity among studies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this meta-analysis of 4 RCTs, early AVR was associated with a significant reduction in unplanned cardiovascular or HF hospitalization and stroke and no differences in all-cause and cardiovascular mortality compared with CS.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39641732/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39641732</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.006>10.1016/j.jacc.2024.11.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39641732</guid>
<pubDate>Fri, 06 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Philippe Généreux</dc:creator>
<dc:creator>Marko Banovic</dc:creator>
<dc:creator>Duk-Hyun Kang</dc:creator>
<dc:creator>Gennaro Giustino</dc:creator>
<dc:creator>Bernard D Prendergast</dc:creator>
<dc:creator>Brian R Lindman</dc:creator>
<dc:creator>David E Newby</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:creator>Björn Redfors</dc:creator>
<dc:creator>Neil J Craig</dc:creator>
<dc:creator>Jozef Bartunek</dc:creator>
<dc:creator>Allan Schwartz</dc:creator>
<dc:creator>Roxanna Seyedin</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Marc R Dweck</dc:creator>
<dc:date>2024-12-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Aortic Valve Replacement vs Clinical Surveillance in Asymptomatic Severe Aortic Stenosis: A Systematic Review and Meta-Analysis</dc:title>
<dc:identifier>pmid:39641732</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.006</dc:identifier>
</item>
<item>
<title>The genomic origin of early maize in eastern North America</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39637852/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>Indigenous maize varieties from eastern North America have played an outsized role in breeding programs, yet their early origins are not fully understood. We generated paleogenomic data to reconstruct how maize first reached this region and how it was selected during the process. Genomic ancestry analyses reveal recurrent movements northward from different parts of Mexico, likely culminating in at least two dispersals from the US Southwest across the Great Plains to the Ozarks and beyond. We...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 26:S0092-8674(24)01277-7. doi: 10.1016/j.cell.2024.11.003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Indigenous maize varieties from eastern North America have played an outsized role in breeding programs, yet their early origins are not fully understood. We generated paleogenomic data to reconstruct how maize first reached this region and how it was selected during the process. Genomic ancestry analyses reveal recurrent movements northward from different parts of Mexico, likely culminating in at least two dispersals from the US Southwest across the Great Plains to the Ozarks and beyond. We find that 1,000-year-old Ozark specimens carry a highly differentiated wx1 gene, which is involved in the synthesis of amylose, highlighting repeated selective pressures on the starch metabolic pathway throughout maize's domestication. This population shows a close affinity with the lineage that ultimately became the Northern Flints, a major contributor to modern commercial maize.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39637852/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39637852</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.003>10.1016/j.cell.2024.11.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39637852</guid>
<pubDate>Thu, 05 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Jazmín Ramos-Madrigal</dc:creator>
<dc:creator>Gayle J Fritz</dc:creator>
<dc:creator>Bryon Schroeder</dc:creator>
<dc:creator>Bruce Smith</dc:creator>
<dc:creator>Fátima Sánchez-Barreiro</dc:creator>
<dc:creator>Christian Carøe</dc:creator>
<dc:creator>Anne Kathrine Wiborg Runge</dc:creator>
<dc:creator>Sarah Boer</dc:creator>
<dc:creator>Krista McGrath</dc:creator>
<dc:creator>Filipe G Vieira</dc:creator>
<dc:creator>Shanlin Liu</dc:creator>
<dc:creator>Rute R da Fonseca</dc:creator>
<dc:creator>Chunxue Guo</dc:creator>
<dc:creator>Guojie Zhang</dc:creator>
<dc:creator>Bent Petersen</dc:creator>
<dc:creator>Thomas Sicheritz-Pontén</dc:creator>
<dc:creator>Shyam Gopalakrishnan</dc:creator>
<dc:creator>M Thomas P Gilbert</dc:creator>
<dc:creator>Nathan Wales</dc:creator>
<dc:date>2024-12-05</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The genomic origin of early maize in eastern North America</dc:title>
<dc:identifier>pmid:39637852</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.003</dc:identifier>
</item>
<item>
<title>Salt's Sex-Specific Impact of Gut Microbiota in Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39636968/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 6;135(12):1138-1140. doi: 10.1161/CIRCRESAHA.124.325719. Epub 2024 Dec 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39636968/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39636968</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11623195/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">PMC11623195</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325719>10.1161/CIRCRESAHA.124.325719</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39636968</guid>
<pubDate>Thu, 05 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Selam Desta</dc:creator>
<dc:creator>Claude F Albritton</dc:creator>
<dc:creator>Annet Kirabo</dc:creator>
<dc:date>2024-12-05</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Salt's Sex-Specific Impact of Gut Microbiota in Hypertension</dc:title>
<dc:identifier>pmid:39636968</dc:identifier>
<dc:identifier>pmc:PMC11623195</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325719</dc:identifier>
</item>
<item>
<title>Correction to: Blunted Cardiac Mitophagy in Response to Metabolic Stress Contributes to HFpEF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39636967/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 6;135(12):e154. doi: 10.1161/RES.0000000000000702. Epub 2024 Dec 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39636967/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39636967</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000702>10.1161/RES.0000000000000702</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39636967</guid>
<pubDate>Thu, 05 Dec 2024 06:00:00 -0500</pubDate>
<dc:date>2024-12-05</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Correction to: Blunted Cardiac Mitophagy in Response to Metabolic Stress Contributes to HFpEF</dc:title>
<dc:identifier>pmid:39636967</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000702</dc:identifier>
</item>
<item>
<title>In This Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39636965/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 6;135(12):1119. doi: 10.1161/RES.0000000000000703. Epub 2024 Dec 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39636965/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39636965</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000703>10.1161/RES.0000000000000703</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39636965</guid>
<pubDate>Thu, 05 Dec 2024 06:00:00 -0500</pubDate>
<dc:date>2024-12-05</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>In This Issue</dc:title>
<dc:identifier>pmid:39636965</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000703</dc:identifier>
</item>
<item>
<title>Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39633578/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study establishes a new class of low penetrance sarcomere variants that are relatively common in the population. When penetrant, isolated LowSVs cause mild HCM. In combination with pathogenic sarcomere variants, LowSVs markedly increase disease severity, supporting a clinically significant additive effect. Last, LowSVs also contribute to age-related remodeling even in the absence of overt HCM.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 5. doi: 10.1161/CIRCULATIONAHA.124.069398. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Classically, hypertrophic cardiomyopathy (HCM) has been viewed as a single-gene (monogenic) disease caused by pathogenic variants in sarcomere genes. Pathogenic sarcomere variants are individually rare and convey high risk for developing HCM (highly penetrant). Recently, important polygenic contributions have also been characterized. Low penetrance sarcomere variants (LowSVs) at intermediate frequencies and effect sizes have not been systematically investigated. We hypothesize that LowSVs may be common in HCM with substantial influence on disease risk and severity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Among all sarcomere variants observed in the Sarcomeric Human Cardiomyopathy Registry (SHaRe), we identified putative LowSVs defined by (1) population frequency greater than expected for highly penetrant (monogenic) HCM (allele frequency >;5×10<sup>-5</sup> in the Genome Aggregation Database, gnomAD) and (2) moderate enrichment (>;2×) in patients with HCM compared with gnomAD. LowSVs were examined for their association with disease severity and clinical outcomes. Functional effects of selected LowSVs were assessed using induced pluripotent stem cell-derived cardiomyocytes. Association of LowSVs with HCM-adjacent traits in the general population was tested using UK Biobank cardiac magnetic resonance imaging data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 6045 patients and 1159 unique variants in sarcomere genes, 12 LowSVs were identified. LowSVs were collectively common in the general population (1:350) and moderately enriched in HCM (aggregate odds ratio, 14.9 [95% CI, 12.5-17.9]). Isolated LowSVs were associated with an older age of HCM diagnosis and fewer adverse events. However, LowSVs in combination with a pathogenic sarcomere variant conferred higher morbidity (eg, composite adverse event hazard ratio, 5.4 [95% CI, 3.0-9.8] versus single pathogenic sarcomere variant, 2.0 [95% CI, 1.8-2.2]; <i>P</i>&lt;0.001). An intermediate functional impact was validated for 2 specific LowSVs-<i>MYBPC3</i> c.442G>;A (partial splice gain) and <i>TNNT2</i> c.832C>;T (intermediate effect on contractile mechanics). Cardiac magnetic resonance imaging analysis of the general population revealed 5 of 12 LowSVs were significantly associated with HCM-adjacent traits without overt HCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study establishes a new class of low penetrance sarcomere variants that are relatively common in the population. When penetrant, isolated LowSVs cause mild HCM. In combination with pathogenic sarcomere variants, LowSVs markedly increase disease severity, supporting a clinically significant additive effect. Last, LowSVs also contribute to age-related remodeling even in the absence of overt HCM.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39633578/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39633578</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069398>10.1161/CIRCULATIONAHA.124.069398</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39633578</guid>
<pubDate>Thu, 05 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Joshua K Meisner</dc:creator>
<dc:creator>Aaron Renberg</dc:creator>
<dc:creator>Eric D Smith</dc:creator>
<dc:creator>Yao-Chang Tsan</dc:creator>
<dc:creator>Brynn Elder</dc:creator>
<dc:creator>Abbey Bullard</dc:creator>
<dc:creator>Owen Merritt</dc:creator>
<dc:creator>Sean L Zheng</dc:creator>
<dc:creator>Neal Lakdawala</dc:creator>
<dc:creator>Anjali Owens</dc:creator>
<dc:creator>Thomas D Ryan</dc:creator>
<dc:creator>Erin M Miller</dc:creator>
<dc:creator>Joseph Rossano</dc:creator>
<dc:creator>Kimberly Y Lin</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Euan Ashley</dc:creator>
<dc:creator>Michelle Michels</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:creator>John C Stendahl</dc:creator>
<dc:creator>Dominic Abrahams</dc:creator>
<dc:creator>Christopher Semsarian</dc:creator>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Matthew Wheeler</dc:creator>
<dc:creator>Jodie Ingles</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Mark W Russell</dc:creator>
<dc:creator>Michael Previs</dc:creator>
<dc:creator>Carolyn Ho</dc:creator>
<dc:creator>James S Ware</dc:creator>
<dc:creator>Adam S Helms</dc:creator>
<dc:date>2024-12-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:39633578</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069398</dc:identifier>
</item>
<item>
<title>Sickle Trait and Alpha Thalassemia Increase NOS-Dependent Vasodilation of Human Arteries Through Disruption of Endothelial Hemoglobin-eNOS Interactions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39633569/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Alpha and beta globin subunits of hemoglobin interact with eNOS to restrict NO signaling in human resistance arteries. Malaria-protective genetic variants that alter the expression of alpha globin or the structure of beta globin are associated with increased NOS-dependent vasodilation. Targeting the hemoglobin-eNOS interface could potentially improve NO signaling in diseases of endothelial dysfunction such as severe malaria or chronic cardiovascular conditions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 5. doi: 10.1161/CIRCULATIONAHA.123.066003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Severe malaria is associated with impaired nitric oxide (NO) synthase (NOS)-dependent vasodilation, and reversal of this deficit improves survival in murine models. Malaria might have selected for genetic polymorphisms that increase endothelial NO signaling and now contribute to heterogeneity in vascular function among humans. One protein potentially selected for is alpha globin, which, in mouse models, interacts with endothelial NOS (eNOS) to negatively regulate NO signaling. We sought to evaluate the impact of alpha globin gene deletions on NO signaling and unexpectedly found human arteries use not only alpha but also beta globin to regulate eNOS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The eNOS-hemoglobin complex was characterized by multiphoton imaging, gene expression analysis, and coimmunoprecipitation studies of human resistance arteries. Novel contacts between eNOS and hemoglobin were mapped using molecular modeling and simulation. Pharmacological or genetic disruption of the eNOS-hemoglobin complex was evaluated using pressure myography. The association between alpha globin gene deletion and blood pressure was assessed in a population study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Alpha and beta globin transcripts were detected in the endothelial layer of the artery wall. Imaging colocalized alpha and beta globin proteins with eNOS at myoendothelial junctions. Immunoprecipitation demonstrated that alpha globin and beta globin form a complex with eNOS and cytochrome b5 reductase. Modeling predicted negatively charged glutamic acids at positions 6 and 7 of beta globin to interact with positively charged arginines at positions 97 and 98 of eNOS. Arteries from donors with a glutamic acid-to-valine substitution at beta globin position 6 (sickle trait) exhibited increased NOS-dependent vasodilation. Alpha globin gene deletions were associated with decreased arterial alpha globin expression, increased NOS-dependent vasodilation, and lower blood pressure. Mimetic peptides that targeted the interactions between hemoglobin and eNOS recapitulated the effects of these genetic variants on human arterial vasoreactivity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Alpha and beta globin subunits of hemoglobin interact with eNOS to restrict NO signaling in human resistance arteries. Malaria-protective genetic variants that alter the expression of alpha globin or the structure of beta globin are associated with increased NOS-dependent vasodilation. Targeting the hemoglobin-eNOS interface could potentially improve NO signaling in diseases of endothelial dysfunction such as severe malaria or chronic cardiovascular conditions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39633569/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39633569</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066003>10.1161/CIRCULATIONAHA.123.066003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39633569</guid>
<pubDate>Thu, 05 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Steven D Brooks</dc:creator>
<dc:creator>A Parker Ruhl</dc:creator>
<dc:creator>Xianke Zeng</dc:creator>
<dc:creator>Phillip Cruz</dc:creator>
<dc:creator>Sergio A Hassan</dc:creator>
<dc:creator>Olena Kamenyeva</dc:creator>
<dc:creator>Md Abdul Hakim</dc:creator>
<dc:creator>Lauryn A Ridley</dc:creator>
<dc:creator>Bianca M Nagata</dc:creator>
<dc:creator>Juraj Kabat</dc:creator>
<dc:creator>Sundar Ganesan</dc:creator>
<dc:creator>Rachel L Smith</dc:creator>
<dc:creator>Mary Jackson</dc:creator>
<dc:creator>Jessica Nino de Rivera</dc:creator>
<dc:creator>Alison J McLure</dc:creator>
<dc:creator>Jarrett M Jackson</dc:creator>
<dc:creator>Robert O Emeh</dc:creator>
<dc:creator>Naomi Tesfuzigta</dc:creator>
<dc:creator>Kyeisha Laurence</dc:creator>
<dc:creator>Stacy Joyce</dc:creator>
<dc:creator>Christina Yek</dc:creator>
<dc:creator>Sophana Chea</dc:creator>
<dc:creator>Derron A Alves</dc:creator>
<dc:creator>Brant E Isakson</dc:creator>
<dc:creator>Jessica Manning</dc:creator>
<dc:creator>Jeremy L Davis</dc:creator>
<dc:creator>Hans C Ackerman</dc:creator>
<dc:date>2024-12-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Sickle Trait and Alpha Thalassemia Increase NOS-Dependent Vasodilation of Human Arteries Through Disruption of Endothelial Hemoglobin-eNOS Interactions</dc:title>
<dc:identifier>pmid:39633569</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066003</dc:identifier>
</item>
<item>
<title>REPLY: Exercise-Based Cardiac Rehabilitation and Coronary Sinus Reducer in the Management of Stable Angina</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39632009/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 10;84(24):e341-e342. doi: 10.1016/j.jacc.2024.09.1228.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39632009/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39632009</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1228>10.1016/j.jacc.2024.09.1228</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39632009</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Rocco A Montone</dc:creator>
<dc:creator>Riccardo Rinaldi</dc:creator>
<dc:creator>Giuseppe Andò</dc:creator>
<dc:creator>Pasquale Perrone Filardi</dc:creator>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>REPLY: Exercise-Based Cardiac Rehabilitation and Coronary Sinus Reducer in the Management of Stable Angina</dc:title>
<dc:identifier>pmid:39632009</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1228</dc:identifier>
</item>
<item>
<title>Optimizing Management of Stable Angina: Lifestyle Intervention as the Third Pillar</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39632008/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 10;84(24):e339-e340. doi: 10.1016/j.jacc.2024.08.082.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39632008/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39632008</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.082>10.1016/j.jacc.2024.08.082</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39632008</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Iris A de Koning</dc:creator>
<dc:creator>Tom Vromen</dc:creator>
<dc:creator>Joyce M Heutinck</dc:creator>
<dc:creator>Hareld M C Kemps</dc:creator>
<dc:creator>Dick H J Thijssen</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Optimizing Management of Stable Angina: Lifestyle Intervention as the Third Pillar</dc:title>
<dc:identifier>pmid:39632008</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.082</dc:identifier>
</item>
<item>
<title>The Reducer Is a Novel, Safe, and Effective Therapy to Optimize the Management of Patients With Stable Angina</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39632007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 10;84(24):e337. doi: 10.1016/j.jacc.2024.08.083.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39632007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39632007</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.083>10.1016/j.jacc.2024.08.083</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39632007</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Shmuel Banai</dc:creator>
<dc:creator>Amir Lerman</dc:creator>
<dc:creator>Stefan Verheye</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Reducer Is a Novel, Safe, and Effective Therapy to Optimize the Management of Patients With Stable Angina</dc:title>
<dc:identifier>pmid:39632007</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.083</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39632006/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 10;84(24):2416. doi: 10.1016/j.jacc.2024.10.107.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39632006/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39632006</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.107>10.1016/j.jacc.2024.10.107</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39632006</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:date>2024-12-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:39632006</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.107</dc:identifier>
</item>
<item>
<title>Major Bleeding and Mortality After Revascularization of Left Main Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39632005/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In the EXCEL trial, CABG resulted in higher 5-year rates of all MB and in-hospital MB, although postdischarge MB was more frequent after PCI. MB after both procedures was associated with increased cardiovascular and noncardiovascular mortality within 5 years. (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization [EXCEL]; NCT01205776).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 10;84(24):2335-2346. doi: 10.1016/j.jacc.2024.07.065.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The incidence and prognostic impact of major bleeding (MB) after percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) for left main coronary artery disease (LMCAD) are unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to investigate the rates and outcomes of MB after LMCAD revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In the EXCEL (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial, 1,905 patients with unprotected LMCAD were randomized to undergo PCI (n = 948) or CABG (n = 957) and followed up for 5 years. MB was defined as TIMI major or minor bleeding, BARC (Bleeding Academic Research Consortium) types 3 to 5 bleeding, or any overt bleeding requiring blood transfusion. The association between MB and subsequent mortality was assessed in time-adjusted Cox regression models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At 5 years, 217 patients (11.4%) had at least 1 MB event. Rates of 5-year MB were 7.9% after PCI vs 14.8% after CABG (OR: 0.48; 95% CI: 0.36-0.65; P &lt; 0.0001). However, in-hospital MB was lower after PCI (3.8% vs 13.5%; OR: 0.25; 95% CI: 0.17-0.37), whereas postdischarge MB was lower after CABG (4.5% vs 2.0%; OR: 2.33; 95% CI: 1.33-3.09; P<sub>interaction</sub> &lt; 0.0001). All 41 postdischarge MB events after PCI occurred in patients receiving dual antiplatelet therapy. MB events within 5 years were associated with a higher subsequent risk of all-cause mortality (adjusted HR: 2.71; 95% CI: 1.95-3.77; P &lt; 0.0001), whether in-hospital or postdischarge (P<sub>interaction</sub> = 1.00) and after both PCI and CABG (P<sub>interaction</sub> = 0.95), driven both by increased cardiovascular and non-cardiovascular mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In the EXCEL trial, CABG resulted in higher 5-year rates of all MB and in-hospital MB, although postdischarge MB was more frequent after PCI. MB after both procedures was associated with increased cardiovascular and noncardiovascular mortality within 5 years. (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization [EXCEL]; NCT01205776).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39632005/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39632005</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.065>10.1016/j.jacc.2024.07.065</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39632005</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Gennaro Giustino</dc:creator>
<dc:creator>Joseph F Sabik</dc:creator>
<dc:creator>Patrick W Serruys</dc:creator>
<dc:creator>John D Puskas</dc:creator>
<dc:creator>Dimitri Karmpaliotis</dc:creator>
<dc:creator>David E Kandzari</dc:creator>
<dc:creator>Marie-Claude Morice</dc:creator>
<dc:creator>Michael Ragosta</dc:creator>
<dc:creator>Zixuan Zhang</dc:creator>
<dc:creator>Ovidiu Dressler</dc:creator>
<dc:creator>Bjorn Redfors</dc:creator>
<dc:creator>Ori Ben-Yehuda</dc:creator>
<dc:creator>Samin K Sharma</dc:creator>
<dc:creator>Arie Pieter Kappetein</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Major Bleeding and Mortality After Revascularization of Left Main Disease</dc:title>
<dc:identifier>pmid:39632005</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.065</dc:identifier>
</item>
<item>
<title>Structure-guided design of a peripherally restricted chemogenetic system</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39631393/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>Designer receptors exclusively activated by designer drugs (DREADDs) are chemogenetic tools for remotely controlling cellular signaling, neural activity, behavior, and physiology. Using a structure-guided approach, we provide a peripherally restricted Gi-DREADD, hydroxycarboxylic acid receptor DREADD (HCAD), whose native receptor is minimally expressed in the brain, and a chemical actuator that does not cross the blood-brain barrier (BBB). This was accomplished by combined mutagenesis, analoging...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 25:S0092-8674(24)01275-3. doi: 10.1016/j.cell.2024.11.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Designer receptors exclusively activated by designer drugs (DREADDs) are chemogenetic tools for remotely controlling cellular signaling, neural activity, behavior, and physiology. Using a structure-guided approach, we provide a peripherally restricted Gi-DREADD, hydroxycarboxylic acid receptor DREADD (HCAD), whose native receptor is minimally expressed in the brain, and a chemical actuator that does not cross the blood-brain barrier (BBB). This was accomplished by combined mutagenesis, analoging via an ultra-large make-on-demand library, structural determination of the designed DREADD receptor via cryoelectron microscopy (cryo-EM), and validation of HCAD function. Expression and activation of HCAD in dorsal root ganglion (DRG) neurons inhibit action potential (AP) firing and reduce both acute and tissue-injury-induced inflammatory pain. The HCAD chemogenetic system expands the possibilities for studying numerous peripheral systems with little adverse effects on the central nervous system (CNS). The structure-guided approach used to generate HCAD also has the potential to accelerate the development of emerging chemogenetic tools for basic and translational sciences.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39631393/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39631393</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.001>10.1016/j.cell.2024.11.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39631393</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Hye Jin Kang</dc:creator>
<dc:creator>Brian E Krumm</dc:creator>
<dc:creator>Adrien Tassou</dc:creator>
<dc:creator>Matan Geron</dc:creator>
<dc:creator>Jeffrey F DiBerto</dc:creator>
<dc:creator>Nicholas J Kapolka</dc:creator>
<dc:creator>Ryan H Gumpper</dc:creator>
<dc:creator>Kensuke Sakamoto</dc:creator>
<dc:creator>D Dewran Kocak</dc:creator>
<dc:creator>Reid H J Olsen</dc:creator>
<dc:creator>Xi-Ping Huang</dc:creator>
<dc:creator>Shicheng Zhang</dc:creator>
<dc:creator>Karen L Huang</dc:creator>
<dc:creator>Saheem A Zaidi</dc:creator>
<dc:creator>MyV T Nguyen</dc:creator>
<dc:creator>Min Jeong Jo</dc:creator>
<dc:creator>Vsevolod Katritch</dc:creator>
<dc:creator>Jonathan F Fay</dc:creator>
<dc:creator>Grégory Scherrer</dc:creator>
<dc:creator>Bryan L Roth</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structure-guided design of a peripherally restricted chemogenetic system</dc:title>
<dc:identifier>pmid:39631393</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.001</dc:identifier>
</item>
<item>
<title>Transthyretin Tetramer Destabilization and Increased Mortality in the General Population</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39630472/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241207011457&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Transthyretin tetramer destabilization was associated with all-cause and cardiovascular mortality in the Danish general population. These findings may suggest a need for large-scale assays to measure transthyretin destabilization for detection of transthyretin amyloidosis before clinical manifestations emerge, since early treatment improves the prognosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 4:e244102. doi: 10.1001/jamacardio.2024.4102. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Transthyretin tetramer destabilization is the rate-limiting step in the development of transthyretin cardiac amyloidosis, an underrecognized contributor to mortality in older adults.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To test the hypothesis that transthyretin tetramer destabilization is associated with all-cause and cardiovascular mortality in the general population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: In this cohort study including individuals aged 20 to 80 years, genetic data were analyzed from 2 similar prospective studies of the Danish general population, the Copenhagen City Heart Study (CCHS) and the Copenhagen General Population Study (CGPS). Observational data from a subsample of the same studies where transthyretin was measured consecutively were also analyzed. In both studies, individuals were followed up from the examination date (1991-1994 in CCHS and 2003-2015 in CGPS) until death or the end of follow-up in December 2018. Data were analyzed from November 1, 2023, to August 15, 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Missense variants in TTR associated with increasing transthyretin tetramer destabilization in primary genetic analyses, and plasma transthyretin level in secondary observational analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: All-cause and cardiovascular mortality identified from the national Danish Civil Registration System and the national Danish Register of Causes of Death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 102 204 individuals (median [IQR] age, 57 [47-66] years; 56 445 [55%] female) were included. Median follow-up was 10 years (range, &lt;1-27 years). In genetic analyses, p.T139M, a transthyretin tetramer stabilizing variant that is more stable than noncarriers' tetramer stability, was used as the reference. For noncarriers who have intermediate tetramer stability and for heterozygotes for amyloidogenic variants (p.V142I, p.H110N, and p.D119N) who have the lowest tetramer stability, respective hazard ratios (HRs) were 1.37 (95% CI, 1.06-1.77) and 1.65 (95% CI, 0.95-2.88) for all-cause mortality (P for trend = .01), and 1.63 (95% CI, 0.92-2.89) and 2.23 (95% CI, 0.78-6.34) for cardiovascular mortality (P for trend = .06). Furthermore, compared with p.T139M, plasma transthyretin decreased stepwise by TTR genotype: -18% for noncarriers and -29% for heterozygotes for amyloidogenic variants (p.V142I, p.H110N, p.D119N; P for trend &lt; .001). Therefore, genetically determined, increasingly lower plasma transthyretin could be considered a surrogate marker for transthyretin tetramer destabilization. Observationally, among 19 619 individuals, noncarriers with plasma transthyretin concentrations less than 20 mg/dL vs 20 to 40 mg/dL had HRs of 1.12 (95% CI, 1.02-1.23) for all-cause mortality and 1.16 (95% CI, 0.97-1.39) for cardiovascular mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Transthyretin tetramer destabilization was associated with all-cause and cardiovascular mortality in the Danish general population. These findings may suggest a need for large-scale assays to measure transthyretin destabilization for detection of transthyretin amyloidosis before clinical manifestations emerge, since early treatment improves the prognosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39630472/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">39630472</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11618624/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241207011457&v=2.18.0.post9+e462414">PMC11618624</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4102>10.1001/jamacardio.2024.4102</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39630472</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Mette Christoffersen</dc:creator>
<dc:creator>Anders Møller Greve</dc:creator>
<dc:creator>Louise Stig Hornstrup</dc:creator>
<dc:creator>Ruth Frikke-Schmidt</dc:creator>
<dc:creator>Børge Grønne Nordestgaard</dc:creator>
<dc:creator>Anne Tybjærg-Hansen</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Transthyretin Tetramer Destabilization and Increased Mortality in the General Population</dc:title>
<dc:identifier>pmid:39630472</dc:identifier>
<dc:identifier>pmc:PMC11618624</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4102</dc:identifier>
</item>





























</channel>
</rss>